Does lisdexamfetamine dimesylate have a clinically meaningful effect on extended-release guanfacine exposure?

Lisdexamfetamine dimesylate increased extended-release guanfacine maximum plasma concentration by 19% and exposure (AUC) by 7% in an interaction study, but these changes are not expected to be clinically meaningful.